NexgenRx Inc. (NEGXF)
Chart Events
Performance Outlook
| Previous Close | 0.2021 |
| Open | 0.2022 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.2021 - 0.2021 |
| 52 Week Range | 0.0110 - 0.3217 |
| Volume | |
| Avg. Volume | 258 |
| Market Cap | 17.428M |
| Beta (5Y Monthly) | 0.14 |
| PE Ratio (TTM) | 9.62 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.01 (132.39%) |
| Ex-Dividend Date | Sep 30, 2022 |
| 1y Target Est | N/A |
- ACCESSWIRE
NexgenRx Announces Q3 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Free Cash Flow
NEXGENRX INC.("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2022, highlighted by continued revenue growth, positive EBIDTA and increased free cash flow. During Q3 2022, the Company showed revenue growth of 15.81% over the same period last year. Revenue for the third quarter was $3,317,358 and $9,401,460 year-to-date.
- ACCESSWIRE
Nexgenrx Announces Declaration Of Dividend
NEXGENRX INC.("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before October 10, 2022 to all shareholders of record as at the close of business on October 3, 2022.
- ACCESSWIRE
NexgenRx Announces Q2 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Increased Free Cash Flow
NEXGENRX INC.("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2022, highlighted by continued revenue growth, positive EBIDTA and increased free cash flow. The Company's Q2 revenue was 12.73% higher compared to the same period last year. Revenue for the second quarter was $3,113,202 and $6,287,078 year to date.
